Talaris Therapeutics to Participate at Two Upcoming Investor Conferences
Talaris Therapeutics, Inc. (Nasdaq: TALS) announced the participation of its senior management team in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Talaris Therapeutics, Inc. (Nasdaq: TALS) announced the participation of its senior management team in two upcoming investor conferences. The first is the Morgan Stanley Healthcare Corporate Access Day on March 29, 2022, at the Boston Harbor Hotel, featuring 1x1 meetings. The second is a Guggenheim Virtual Genomic Medicines and Rare Disease Day on March 31, 2022, with a fireside chat at 3:00 p.m. ET. A live webcast of the Guggenheim event will be available on Talaris' website, with a replay accessible afterward. Talaris focuses on cell therapies for organ transplantation and immune disorders.
Details
News Market Reaction – TALS
The recorded move for TALS in the trading session of this news was +2.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, today announced that members of its senior management team will participate at the following investor conferences:
Morgan Stanley Healthcare Corporate Access Day
Date: Tuesday, March 29, 2022
Location: Boston Harbor Hotel, Boston, MA
1x1 meetings only
Guggenheim Virtual Genomic Medicines and Rare Disease Day
Fireside chat date: Thursday, March 31, 2022
Fireside chat time: 3:00 p.m. ET
A live webcast of the presentation at the Guggenheim Genomic Medicines and Rare Disease Day will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, a replay of the event can be found on the Talaris website.
About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.
Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783
Investor Contact
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
(339) 970-2843
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.